Novocure Ltd Total Liabilities
Novocure Ltd total liabilities. Based on the latest financial reports, Novocure Ltd (NVCR) has total liabilities worth $457.21 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NVCR asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Novocure Ltd (2013–2025)
Total liabilities of Novocure Ltd from 2013 to 2025. This chart illustrates how Novocure Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Novocure Ltd to see how much of total assets are deployed in long-term investments.
Novocure Ltd Competitors by Total Liabilities
The table below lists competitors of Novocure Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
H Lundbeck A/S
CO:HLUN-A
|
Denmark | Dkr29.11 Billion |
|
IGNITIS GRUPE SP.GDR/1
F:IGV
|
Germany | €3.78 Billion |
|
Metrovacesa SA
MC:MVC
|
Spain | €843.82 Million |
|
Cardinal Energy Ltd
TO:CJ
|
Canada | CA$463.32 Million |
|
Yantai Dongcheng Pharmaceutical Co Ltd
SHE:002675
|
China | CN¥3.77 Billion |
|
Beijing Caishikou Department Store Co Ltd
SHG:605599
|
China | CN¥5.05 Billion |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €119.06 Million |
|
China Railway Construction Corporation Limited
F:4FF
|
Germany | €1.70 Trillion |
Liability Composition Analysis (2013–2025)
This chart breaks down Novocure Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NVCR total assets.
Liquidity & Leverage Metrics
Novocure Ltd Total Liabilities Ratios Explained
Novocure Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Novocure Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Novocure Ltd (2013–2025)
The table below shows the annual total liabilities of Novocure Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $463.86 Million | -47.32% |
| 2024-12-31 | $880.61 Million | +12.37% |
| 2023-12-31 | $783.63 Million | +4.42% |
| 2022-12-31 | $750.48 Million | +2.95% |
| 2021-12-31 | $729.00 Million | +26.68% |
| 2020-12-31 | $575.46 Million | +119.93% |
| 2019-12-31 | $261.66 Million | +15.00% |
| 2018-12-31 | $227.53 Million | +49.96% |
| 2017-12-31 | $151.73 Million | +8.59% |
| 2016-12-31 | $139.74 Million | +147.25% |
| 2015-12-31 | $56.52 Million | +182.57% |
| 2014-12-31 | $20.00 Million | +16.75% |
| 2013-12-31 | $17.13 Million | -- |
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TT… Read more